Loading company
InMed Pharmaceuticals Inc.
INM · Nasdaq · ·
Next earnings: November 5, 2026
$1.39+0.7%Sep 29 close
- 1M
- +0.7%
- 6M
- +126.0%
- 1Y
- -36.5%
- 5Y
- -99.8%
INM · Nasdaq · ·
Next earnings: November 5, 2026
$1.39+0.7%Sep 29 close
InMed Pharmaceuticals Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $820.2K | $1.1M | -26.22% |
| Profit | -$5.8M | -$1.8M | -226.53% |
| Profit per share | -$1.43 | -$0.43 | -232.56% |
| Free Cash Flow | -$1M | -$3.3M | +69.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from InMed Pharmaceuticals Inc.’s Item 2.02 8-K filed November 13, 2020; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
InMed Pharmaceuticals Inc. has no earnings call transcript available.